Viking Therapeutics (DE:1VT)
NASDAQ:1VT
1VT Stock Chart & Stats
€29.75
-€0.26(-0.65%)
At close: 4:00 PM EST
€29.75
-€0.26(-0.65%)
Day’s Range― - ―
52-Week Range€19.28 - €39.10
Previous CloseN/A
Volume0.00
Average Volume (3M)210.00
Market Cap
€2.87B
Enterprise Value€3.68B
Total Cash (Recent Filing)€602.96M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Jul 29, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.14
Shares Outstanding116,105,644
10 Day Avg. Volume209
30 Day Avg. Volume210
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)6.20
Price to Sales (P/S)0.00
P/FCF Ratio-14.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€81.02Price Target Upside172.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtMinimal debt materially reduces near-term financial distress risk for a clinical-stage biotech. With little leverage the company retains flexibility to pursue equity raises, partnerships, or milestone financing without immediate debt servicing pressure, supporting program advancement over months.
Substantial Equity Funding BaseA $501.9M equity base provides a tangible funding cushion to finance ongoing clinical programs and regulatory work in the medium term. While declining vs prior years, this capital buffer supports execution of trials and reduces immediate dependency on dilutive financings for several months of operations.
Governance Stability And Board SupportStrong shareholder votes for directors and auditor ratification signal continuity in leadership and oversight. Consistent governance reduces execution risk on clinical programs, helps maintain investor confidence, and eases negotiation of collaborations or financings over the coming quarters.
Bears Say
Pre-revenue Operating ModelBeing pre-revenue means the company relies on external capital rather than product cash flow to fund development. This structural dependence increases dilution and execution risk, constraining strategic options and making sustained investment in trials contingent on successful financing or partnerships.
Accelerating Cash BurnRapidly increasing negative operating cash flow shortens runway and elevates financing urgency. Persistent large cash burn forces recurring capital raises or partnerships, raising dilution risk and potentially delaying programs if funding terms are adverse, impacting long-term ability to complete trials.
Widening Net Losses And Declining EquitySteeply widening losses paired with a marked decline in equity reflect sustained negative economics and dilution. Over months this trend undermines financial flexibility, increases dependency on capital markets, and can constrain investment in high-value programs if fundraising conditions deteriorate.
Viking Therapeutics News
1VT FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was €19.28 and its highest was €39.09 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is €2.87B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Jul 29, 2026 which is in 46 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Apr 29, 2026. The company reported -€1.184 earnings per share for the quarter, missing the consensus estimate of -€0.843 by -€0.34.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -1.07.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 116,105,644 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -€1.184 in its last earnings report, missing expectations of -€0.843. Following the earnings report the stock price went down -4.505%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in DE:1VT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viking Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€81.02 (172.33% Upside)
€81.02 (172.33% Upside)
Blogger Sentiment
Bullish
DE:1VT Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €130.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.59%
12-Months-Change
Fundamentals
Return on Equity
-71.31%
Trailing 12-Months
Asset Growth
-29.84%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
1VT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical and operational progress: compelling Phase II efficacy for both subcutaneous (up to 14.7%) and oral (up to 12.2%, with 80% ≥10% responders), initiation and fast enrollment of Phase III programs, completion of auto-injector bioequivalence enabling device rollout, a completed maintenance study enrollment with results expected Q3 2026, a manufacturing agreement to support commercialization, and expansion of the pipeline with an amylin agonist. Offsetting these positives are sharply higher R&D expenses and widening net losses (large YoY increases), a ~22% decline in cash year-over-year, and a projected quarterly burn of $60M–$90M, alongside marketplace and reimbursement uncertainties. On balance, the operational and clinical milestones materially outweigh the financial and market risks presented on the call.View all DE:1VT earnings summaries1VT Stock 12 Month Forecast
Average Price Target
€81.02
▲(172.33% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Scholar Rock Holding
―
Immunovant
―
NewAmsterdam Pharma Company
―
Options Prices
Currently, No data available
---